The Netherlands Is Losing Its AgriTech Edge—Here's What's at Stake

Jan de Vries · 2026-10-30

The Netherlands has built a reputation as Europe's agricultural powerhouse. Think cutting-edge greenhouses, world-class seed breeders, and a food production system that punches far above its weight. But a new report suggests that crown is starting to slip. Invest-NL, the Dutch national investment institution, just published a study called *Deep Dive Agrifood Biotech*. The message is blunt: the country is great at generating innovation but struggles to turn it into globally competitive businesses. Other nations are simply moving faster to commercialize emerging agricultural technologies. ### The money on the table Here's the number that caught my attention. According to the report, fixing the barriers facing Dutch agrifood biotech companies could unlock roughly $18.5 billion in additional annual revenue by 2040 (that's about €17 billion). But without coordinated action on regulation, financing, and commercialization, much of that opportunity will be captured elsewhere. The study draws on interviews with more than 150 entrepreneurs, investors, researchers, and policymakers, plus investment data stretching from 2010 to April 2026. It focuses on three areas: seed breeding and genetics, biological agricultural inputs, and biotech-derived food ingredients. ### A strong start, a weaker finish This is the part that stings. The Netherlands accounts for 3.3% of BioTech startups worldwide but only 1.3% of scale-ups, according to TNO data cited in the report. In plain terms: the country is excellent at starting things and less successful at growing them. Invest-NL points to three recurring weaknesses: - Too few promising technologies become scalable ventures - Regulatory and validation processes delay market entry - Insufficient financing keeps companies from reaching industrial production The upside is real, though. In a favorable scenario, annual Dutch agrifood BioTech revenues could hit about $27 billion by 2040. Under current conditions, they'd land at just $8.7–9.8 billion. And here's a smart nuance: the Netherlands doesn't need to manufacture everything at home. It should focus on keeping the valuable knowledge, intellectual property, companies, and specialized capabilities—while leaning on European production networks where it makes sense. ### Ten years to say yes One of the most frustrating obstacles involves biological crop protection, where Dutch firms are developing alternatives to conventional chemical pesticides. Getting European regulatory approval for a new biological product can take eight to ten years. The existing frameworks were designed around chemicals, so they fit biological innovations poorly. As a result, some companies launch in Brazil and the United States first, where commercialization moves faster. Invest-NL warns Europe could lose ground in a biological crop protection market that might expand seven- to tenfold by 2040. Food biotechnology faces similar friction. Approval for novel ingredients can take one to three years longer in Europe than in the US, and building a first commercial production facility can run into the tens or even hundreds of millions of dollars. > "Faster approvals should not come at the expense of safety," the report stresses. Instead, regulators should offer earlier guidance, more predictable assessments, and room for companies to validate products under real-world conditions. For fermentation-derived food ingredients alone, favorable conditions could support about $8.7 billion in annual Dutch revenues by 2040—versus roughly $2.2 billion under existing policies. ### The bottom line Innovation isn't the problem. Turning it into scale is. And that's a fixable problem—if the Netherlands decides it's worth fixing.